It could be approved by the FDA as soon as August.
“It saved my life. It saved my marriage. It saved my kids,” Sahar McMahon, a member of the trial study,. “Just, the ricochet effect of sitting around, gaining weight, watching TV, going to sleep on the couch, not interacting with my kids, letting them figure it out, letting them stay up on iPads and tablets. I can’t imagine how much further I could have fallen into a depression.”
The mom of 4-year-old Ophelia and 2-year-old Lenora said that she felt better after just taking one dose of the drug, even though at the time she didn’t know if it was a placebo.It’s not an SSRI. It’s actually a steroid that is a metabolite of progesterone that occurs naturally in the body. It rises during pregnancy and then plummets after the birth of the baby, and it can greatly affect mood, behavior, and cognition.
“Neuroactive steroids are naturally made in the brain and are breakdown products of progesterone that protect brain networks from the damaging effects of stress and maintain healthy brain network functioning,” Deligiannidis told CNN. Some women in the study reported some mild side effects, including dizziness and drowsiness — in those cases, their doses were lowered., which is given to drugs that could significantly improve the treatment of a condition. That means it could be on its way to approval — and on its way to helping a lot of new moms — as soon as August 4.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Postpartum depression pill is safe and effective, new trial data shows | CNNThe day after the trial participants completed a 14-day treatment course of zuranolone, the researchers found that 57% reported a 50% or higher improvement in their depressive symptoms, compared with 38% of those on a placebo.
Read more »
Everything new coming to Max in August 2023 -- and what's leavingGet ready for new seasons of 'Winning Time' and 'Hard Knocks,' an 'Adventure Time' spinoff and more
Read more »